Research Analysts Set Expectations for ZVRA Q4 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their Q4 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings per share of $0.04 for the quarter. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same period last year, the business earned ($0.15) EPS.

ZVRA has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Maxim Group upped their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock. Finally, Roth Mkm increased their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $20.83.

Zevra Therapeutics Trading Down 2.4 %

Shares of NASDAQ:ZVRA opened at $8.45 on Thursday. Zevra Therapeutics has a 52 week low of $4.18 and a 52 week high of $9.09. The company’s 50 day moving average is $7.97 and its two-hundred day moving average is $6.44. The company has a market cap of $444.64 million, a PE ratio of -4.40 and a beta of 1.93. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80.

Institutional Trading of Zevra Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC grew its holdings in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Zevra Therapeutics during the 1st quarter valued at approximately $64,000. The Manufacturers Life Insurance Company grew its position in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at $92,000. Finally, Intech Investment Management LLC bought a new position in Zevra Therapeutics during the 3rd quarter valued at $95,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.